The overall goal of this SPORE in lung cancer proposal is to translate recent advances in the understanding of the molecular pathogenesis of lung cancer into new methods to prevent, diagnose, and treat lung cancer. This SPORE is a logical development of the planning P20 SPORE in Lung Cancer awarded 3 years ago to UTSW. It developed out of 32 years of planning effort between UT Southwestern Medical Center (UTSW) and M.D. Anderson Cancer Center (MDACC), bringing together two major complementary strengths in lung cancer research in the areas of prevention, molecular pathogenesis, early detection, and development of novel therapies based on translational research. This SPORE consists of 5 inter-related projects and 3 supporting Cores. The projects in Lung Cancer are: 1. Identification of 3p Recessive Oncogenes; 2. Genetic Susceptibility: 3. Molecular Early Detection; 4. Chemoprevention in Former Smoker; 5. Mutant p53 Epitope Targeting. The Cores are: A. Administrative; B. Pathology and Tissue Resource; and C. Informatics. All of the scientific projects are: a) translational in nature; b) focus on human lung cancer; c) arose out of conjoint planning between UTSW and MDACC and involve investigators from both institutions as Co- investigators; d) interact with other projects; e) include basic and clinical investigators; and f) utilize Core resources. There is a substantial plan for innovative Developmental Projects, and a plan for Career Development that has already been productive from the UTSW P20 planning SPORE effort. There is a heavy emphasis on prevention, early detection and the development of novel therapies that could be applied to very early stage disease. In addition, the Developmental Program includes a project for the testing for genetic predisposition to nicotine dependency as a new approach to identifying persons at high risk of developing lung cancer. Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA070907-03S2
Application #
6077102
Study Section
Special Emphasis Panel (SRC (08))
Program Officer
Ujhazy, Peter
Project Start
1996-09-30
Project End
1999-08-31
Budget Start
1998-09-01
Budget End
1999-08-31
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Mender, Ilgen; LaRanger, Ryan; Luitel, Krishna et al. (2018) Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 20:826-837
Gong, Ke; Guo, Gao; Gerber, David E et al. (2018) TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 128:2500-2518
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835

Showing the most recent 10 out of 1059 publications